Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance study of radiolabeled migalastat in healthy volunteers
NL-OMON35820Phase 1Active, not recruiting
- Sponsor
- Amicus Therapeutics
- Start
- Aug 2011
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of migalastat in Fabry disease (FD), sponsored by Amicus Therapeutics. Primary endpoints: Total radioactivity in plasma, urine, and feces, Cumulative excretion in urine and feces and 4 more. Started Aug 2011; status: active, not recruiting.
02
Drugs
migalastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON35820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35820.